Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Agreement to Supply PEX010 to Linkoping University for PsiloSAD Trial in Social Anxiety Disorder
The agreement adds a university clinical-trial supply relationship for Filament's botanical psilocybin drug candidate.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rhelion Life Sciences (TRUFF), through wholly owned subsidiary Filament Health, signed an agreement to supply PEX010 to Linköping University for PsiloSAD. The supply and licensing agreement covers Filament's botanical psilocybin drug candidate for a clinical trial evaluating psilocybin in social anxiety disorder.
Linköping University in Sweden sponsors the trial, which is led by Professor Markus Heilig. Filament is not the sponsor and is not responsible for conducting the trial. Rhelion completed its acquisition of Filament on April 30, 2026, including PEX010 and a portfolio of 78 issued patents across 13 patent families.
Positive
- Minor pointFilament's signed supply and licensing agreement covers PEX010 for Linköping University's social anxiety disorder trial.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Filament has signed a supply and licensing agreement with Linköping University in Sweden for PEX010 in the PsiloSAD clinical trial in social anxiety disorder.
Toronto, Ontario--(Newsfile Corp. - October 28, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament Health Corp. ("Filament"), the Company develops, manufactures and supplies PEX010, its patented, standardized, GMP manufactured botanical psilocybin drug candidate, to clinical research and compassionate access programs at leading institutions worldwide.
The Company is pleased to announce that Filament has entered into a supply and licensing agreement with Linköping University for the supply of PEX010 to the clinical trial known as PsiloSAD (EU CT 2026-526267-37-00).
PsiloSAD will evaluate psilocybin for social anxiety disorder. The trial is led by Professor Markus Heilig at Linköping University. Linköping University is the sponsor of the trial. Filament is not the sponsor of the trial and is not responsible for its conduct.
"We continue to be a sought-after global supplier of naturally derived, pharmaceutical-grade psilocybin, and PEX010 remains at the forefront of botanical psilocybin research," said Todd Shapiro, Chief Executive Officer of Rhelion Life Sciences. "This agreement with Linköping University further reinforces Filament Health's position as a global leader and reflects the confidence that respected research institutions place in the consistency, quality and reliability of our drug candidate. We are proud to support important research."
PEX010, Filament Health's botanical psilocybin drug candidate, underscores Filament's position as a leading supplier of pharmaceutical grade natural psilocybin, supporting more than 80 academic and philanthropic research studies worldwide. PEX010 is available in a standardized dosing range of 1, 5 and 25 mg from a single drug candidate, with a 0.5 mg dose to follow, produced using Filament's proprietary and patented extraction, purification and stabilization methods, giving investigators consistent composition across every dose, every study and every research site. On April 30, 2026, the Company completed its previously announced acquisition of Filament Health Corp., including its lead drug candidate, PEX010, and its portfolio of 78 issued patents across 13 patent families.
About Rhelion Life Sciences:
Rhelion Life Sciences is a science and research led company advancing the natural psychedelic drug discovery and development sector. Through its wholly owned subsidiary Filament Health Corp., the Company is developing naturally derived psilocybin drug candidates, including its patented PEX010, and supporting clinical research and compassionate use programs with leading institutions around the world.
For additional information:
Todd Shapiro
Chief Executive Officer & Director
Tel: 647-204-7129
Email: todd@rhelion.com
Website: www.Rhelion.com
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current conditions but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Examples of such information include statements with respect to: the supply of PEX010 to Linköping University for the PsiloSAD trial; the submission, approval, conduct and progress of the trial; the therapeutic potential of psilocybin and PEX010, including for social anxiety disorder; the obtaining and maintenance of the regulatory authorizations, including clinical trial, import and export authorizations, required to supply PEX010 into Sweden; demand for standardized natural psilocybin; the anticipated future availability of a 0.5 mg dose alongside the existing 1, 5 and 25 mg doses; the completed acquisition of Filament Health and the expected integration of Filament's clinical infrastructure and intellectual property; and the future development, commercialization and regulatory approval of PEX010.
Forward-looking information in this news release is based on certain assumptions and expected future events, namely: the continued ability of Filament and Psilo Scientific Ltd. to manufacture and supply PEX010; the performance by Linköping University and Filament of their respective obligations under the supply and licensing agreement; the approval of the trial by the relevant regulatory authorities and ethics committee; the ability to obtain and maintain any required regulatory permits and approvals, including clinical trial, ethics, import and export authorizations; the successful integration of Filament Health following the completed acquisition; and general business, market and economic conditions. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, namely: the risk that either party does not perform its obligations under the supply and licensing agreement; the risk that the supplied product does not meet specification on release testing; the risk that the trial is not approved, or does not proceed or enrol participants as anticipated; the risk that the trial does not produce positive or clinically meaningful results; delays in regulatory permitting, including clinical trial, ethics, import and export authorizations; regulatory or enforcement developments affecting the legal framework for psilocybin supply and research; the risk that the 0.5 mg dose does not become available as anticipated; the risk that integration of Filament Health is not completed as anticipated; and adverse changes in the regulatory or political landscape affecting psychedelic research and access, together with the other risk factors described in the Company's continuous disclosure documents available under the Company's profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned that the foregoing list is not exhaustive.
Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.
Source: Rhelion Life Sciences Corp.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/321406
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What agreement did Rhelion's Filament Health sign with Linköping University?
Filament Health signed a supply and licensing agreement to provide PEX010 for Linköping University's PsiloSAD clinical trial. The trial will evaluate psilocybin for social anxiety disorder.
Who is responsible for the PsiloSAD trial using Filament Health's PEX010?
Linköping University sponsors PsiloSAD, and Professor Markus Heilig leads the trial. Filament is not the sponsor and is not responsible for its conduct.